Marizyme, Inc.

Marizyme is an innovation-driven medical technology and life sciences company focused on the acquisition, development, and commercialization of therapies that minimize mortality and costs in the acute care space. The company operates an integrated portfolio of medical devices and diagnostic platforms spanning cardiac surgery, surgical care, and chronic disease management. Marizyme's flagship product DuraGraft is a first-in-class FDA-cleared intra-operative vascular conduit storage solution for coronary artery bypass grafting (CABG) surgery. The company also develops pipeline products including MATLOC, a point-of-care lab-on-chip diagnostic platform for chronic kidney disease assessment, and Krillase, an Antarctic krill-derived enzyme platform with applications in wound care and veterinary medicine.